US federal prosecutors have subpoenaed Valeant Pharmaceuticals as part of an ... distribution of its products and pricing decisions, as well as "information provided to the Centers for Medicare ...
Valeant Pharmaceuticals International was founded in 2004 and operates in Costa Mesa, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products ...
Valeant Pharmaceuticals (VRX). Sequoia, however, had a successful history of loading up on a stock or two, so I wasn’t particularly worried. For many years, it owned a ton of Berkshire Hathaway ...
Bausch Health, formerly known as Valeant Pharmaceuticals ... Solta Medical and Diversified Products. Bausch Health remains a ...
At a town hall meeting last night, presidential candidate Hillary Clinton vowed to "go after," Valeant Pharmaceuticals, after a woman handed her a note about her diabetes medication. The note said ...
Valeant Pharmaceuticals is trying to acquire Allergan ... from the companies it acquires and just sells their finished products. In a letter to Valeant CEO Pearson, Allergan CEO David Pyott ...
Pharmaceutical Products & Market Valeant - financial key figures 2017 This 2017 business report presents Valeant's course of business throughout the respective business year.
Aug 27 2024 Reply of petitioners Valeant Pharmaceuticals International, Inc., et al. filed. (Distributed) ABOUT RESOURCES JOB POSTINGS PRIVACY POLICY CONTACT US Sign up to receive a daily email digest ...
a first-in-class potassium-channel opener developed by Valeant Pharmaceuticals for the treatment of epilepsy. GSK will also gain the rights to Valeant's back-up compounds that target potassium ...
On Thursday pharmaceutical company Valeant did yet another presentation ... and then uses the revenue from acquired products to hide that lack of growth. At the end of the presentation, a listener ...
limited insight into how past acquisitions and products are performing." Finally it also derided Valeant for "anaemic growth, which Allergan believes is primarily driven by significant price ...